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Abstract. Purpose: Previous studies using dopamine
transporter single-photon emission computed tomography
(SPECT) to try and distinguish between patients with idio-
pathic Parkinson’s disease (IPD) and patients with atypical
parkinsonian syndromes (APS) have mainly focussed on pa-
tients with an already established clinical diagnosis of sev-
eral years’ duration. Differences in the pattern of striatal
involvement between IPD andAPS have been found in only
few studies. We hypothesized that distinguishing SPECT
featuresmight bemost pronounced at an early disease stage,
and the purpose of the present study was to investigate this
hypothesis.
Methods: The study included 72 patients with an initial
clinical diagnosis of IPD, supported by decreased striatal
[123I]β-CIT binding on baseline SPECT. In ten patients, the
diagnosis was changed to APS over a mean follow-up
period of 62 months. We retrospectively compared the pat-
terns of striatal involvement on the baseline SPECT scans
between the group of patients (re)diagnosed with APS and
the remaining 62 patients in whom a diagnosis of IPD was
maintained.
Results: In the group of patients with APS, baseline [123I]β-
CIT binding in both caudate nuclei was lower than in the
group of patients with IPD. In addition, putamen to caudate
binding ratios were higher in the group of APS patients. In
spite of these differences, individual binding values showed
considerable overlap between the groups.
Conclusion: [123I]β-CIT SPECT scanning in early-stage,
untreated parkinsonian patients revealed a relative sparing
of the caudate nucleus in patients with IPD as compared to
patients later (re)diagnosed with APS. Nevertheless, the
pattern of striatal involvement appears to have little pre-
dictive value for a later re-diagnosis of APS in individual
cases.
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Introduction
Two large clinicopathological studies in the early 1990s
showed the accuracy of the clinical diagnosis of idiopathic
Parkinson’s disease (IPD) to be below 80% [1, 2]. A more
recent study using current clinical criteria in 100 patients
diagnosed with IPD showed a diagnostic accuracy of 90%
[3]. In a specialist movement disorder service, the accuracy
of the final clinical diagnosis of IPD even exceeded 98%
[4]. Early in the course of the disease, when differentiating
clinical features may not yet have developed, diagnostic ac-
curacy is probablymuch lower. In the aforementioned study
from a specialized movement disorders service, the initial
clinical diagnosis was changed to one of the so-called atyp-
icalparkinsoniansyndromes(APS) inmore thanone-quarter
of the patients [4]. This “contamination” of the early-stage
IPD populationwith patients suffering fromAPS could lead
to a share of potential non-responders in fuure studies in-
vestigating the effects of neuroprotective agents. Improving
the accuracy of the initial clinical diagnosis of IPD is not
only of importance to future studies of neuroprotective
agents, but would also enable us to provide more reliable
information to patients and caregivers with respect to prog-
nosis and expected response to symptomatic treatment.
In vivo imaging of striatal dopamine transporter (DAT)
binding by means of single-photon emission computed
tomography (SPECT) is a quantitative biomarker for IPD
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onset, severity and progression [5–10]. Previous studies in
which this technique was used to study differences in the
pattern of degeneration of the nigrostriatal system between
IPD and APS have so far shown inconsistent results. In
some, a relative sparing of the caudate nucleus or a higher
degree of asymmetry in striatal involvement distinguished
between IPD and either multiple system atrophy (MSA)
[11] or progressive supranuclear palsy (PSP) [12, 13] at a
group level. In other studies, no differences whatsoever
were found in striatal DAT binding between IPD and APS
[14–16]. The inconsistency in these findings might be ex-
plained by the design of previous studies, in which subjects
were generally included at advanced stages of disease.
Considering the supposedly slower progression of dopami-
nergic hypofunction in the (posterior) putamen as com-
pared with the caudate nucleus in the early phases of IPD
[17], differences in caudate involvement between IPD and
APSmight very well become less pronouncedwith advanc-
ing disease stage. Along the same line of reasoning, faster
progression of dopaminergic hypofunction in the putamen
ipsilateral to the clinically most affected body half [17] can
be expected to reduce the asymmetry of putaminal involve-
ment with disease progression. It is therefore quite likely
that differences in the pattern of dopaminergic hypofunc-
tion between IPD and APS will be most pronounced in the
early stages of disease. Early-stage DAT SPECT imaging
may thus be more sensitive in detecting such changes than
DAT SPECT at later disease stages.
To date, few studies have been conducted to investigate
the effects of treatment with dopaminergic agents on DAT
SPECT binding in IPD patients [18, 19]. Although a
(major) influence of anti-parkinsonian medication on DAT
binding appears to be unlikely, this has not been proven
conclusively. In particular, an influence of dopamine ag-
onists on DAT binding cannot be excluded at present [19].
Most patients included in previous studies comparing DAT
binding between IPD and APS patients were already using
dopaminergic agents. Ideally, the potential value of DAT
SPECT imaging in the differential diagnosis of parkinson-
ism should be assessed before pharmacological treatment is
initiated.
The aim of the present study was to retrospectively com-
pare the patterns of striatal involvement, visualized at
baseline using [123I]β-CIT SPECT scanning in early-stage,
untreated patients with a clinical diagnosis of IPD, be-
tween those subjects in whom the initial diagnosis of IPD
was changed to APS during a mean follow-up period of
62 months and those subjects in whom the initial diag-
nosis of IPD was maintained. In all patients included in
the study, the initial clinical diagnosis of IPD was
supported by a reduction of striatal [123I]β-CIT binding
on the baseline SPECT scan.
The experiments complied with the current laws in The
Netherlands, inclusive of ethics approval.
Materials and methods
Subjects
A total of 77 patients with early-stage, untreated IPD diagnosed
according to the United Kingdom Parkinson’s Disease Society Brain
Bank (UK-PDSBB) clinical diagnostic criteria [20] and reduced
[123I]β-CIT SPECT binding (see data processing section for details
regarding criterion) at the time of the initial clinical diagnosis were
recruited from the outpatient clinic for movement disorders at the VU
University Medical Center (VUMC). In all patients, [123I]β-CIT
SPECT imaging was performed before the initiation of do-
paminomimetic therapy. None of the subjects was using a com-
pound that potentially interferes with [123I]β-CIT SPECT binding
(i.e. amphetamine, cocaine or bupropion). All subjects gave written
informed consent to the research protocol, which was approved by
the local medical ethical committee of the VUMC. Ethics review
criteria conformed to the Helsinki Declaration. Of the total group of
77 patients, four were lost to follow-up and one had an uncertain
diagnosis, leaving a group of 72 patients for further analysis. Disease
duration was calculated on the basis of the patients’ subjective
estimate of the time of occurrence of the first motor symptoms. Side
of onset was based on the body half in which the first clinical (motor)
symptoms occurred. Unified Parkinson’s Disease Rating Scale motor
scores (UPDRS III [21]) were obtained by a trained neurologist.
SPECT imaging
SPECT imaging was performed using a system dedicated to brain
topography, the SME 810X system (Strichman Medical Equipment
Inc., Medfield, MA, USA). The Strichman camera consists of 12
individual crystals each equipped with a focussing collimator. The
transaxial resolution of this camera is 7.6 mm full-width at half-
maximum (FWHM) of a line source in air. Subjects received po-
tassium iodide orally in order to block thyroid uptake of free
radioactive iodine. [123I]β-CIT (Amersham Cygne, Eindhoven, The
Netherlands; specific activity >185 MBq/nmol; radiochemical pu-
rity >99%) was injected intravenously at an approximate dose of
110 mBq. 123I labelling, acquisition, attenuation correction and re-
construction of images were performed as described previously
[22]. Image acquisition was performed 24 h post injection. The
measured concentration of radioactivity was expressed in Strichman
Medical Units (SMUs; 1 SMU=100 Bq/ml as specified by the
manufacturer).
Clinical follow-up
Clinical follow-up was performed by examining patient charts 36–
80 months (mean ± SD, 62±11 months) after [123I]β-CIT SPECT
imaging. Whenever necessary, supplementary data were obtained
during the next scheduled appointment at the outpatient clinic.
Diagnostic criteria used in the re-evaluation of the clinical diagnosis
were the UK-PDSBB clinical diagnostic criteria for IPD [20], the
AAS/AAN criteria for MSA [23], the NINDS-SPSP criteria for PSP
[24] and the consensus criteria for dementia with Lewy bodies
(DLB) [25]. In several patients, data from magnetic resonance im-
aging (MRI, n=11) and/or the results of [123I]iodobenzamide
(IBZM) SPECT scans (n=12) were available. Vascular lesions in
the striatum on so-called fast-FLAIR and/or T2-weighted MRI were
considered supportive of vascular parkinsonism. A hypointense pu-
tamen with a hyperintensive rim and/or hyperintensities in the brain-
stem on fast-FLAIR and/or T2-weighted MRI were considered
supportive of MSA. Reduced D2 binding on IBZM SPECT images
was considered supportive of either MSA or PSP. Re-evaluation of
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the 72 patients with an initial diagnosis of IPD yielded 62 cases of
IPD. In ten patients, the diagnosis of IPD was changed to APS; these
were seven cases of MSA, two cases of DLB and one case of PSP.
Thus, at least 13% of our original study population of 77 patients
were re-diagnosed with APS during the follow-up period. Subject
characteristics at baseline are listed for each group in Table 1.
Data processing
For the analysis of striatal [123I]β-CIT binding, two consecutive
transverse slices representing the most intense striatal binding were
analysed. A standard anatomical region of interest (ROI) template
(constructed according to a stereotactic atlas and including regions
for caudate nucleus, putamen and occipital cortex) was placed bi-
laterally on the images (Fig. 1). Small variations of individual brains
required movement of the fixed ROIs, without changing their size
and shape, within the template for optimal fitting. Estimates of
specific striatal binding were made by subtracting occipital counts
(non-specific binding; mean of the two slices) from striatal counts.
Specific to non-specific [123I]β-CIT binding ratios were then
calculated for left and right putamen and left and right caudate
nucleus. In addition, bilateral putamen to caudate ratios and asym-
metry indices for the putamen and caudate nucleus were computed,
using the following formulas: putamen binding ratio/caudate bind-
ing ratio and |(right binding ratio − left binding ratio)/(right binding
ratio + left binding ratio)|, respectively. Subsequently, all ratios were
recoded into the most symptomatic (contralateral) side and least
symptomatic (ipsilateral) side, based on the side of onset of the first
parkinsonian symptoms. [123I]β-CIT binding was considered ab-
normal, i.e. to reflect degeneration of nigrostriatal dopaminergic
neurons, when the binding ratios of either right or left caudate or
right or left putamen were reduced to more than two SD values from
the mean of healthy controls (control data from our laboratory [26],
n=10, age 44.7±16.9 years, binding ratio left caudate 6.9±1.6, right
caudate 6.9±1.5, left putamen 6.1±2.0, right putamen 6.0±1.6
(mean ± SD)).
Statistical analysis
Group differences between IPD and APS groups in the distribution
of gender, side of onset and modified Hoehn and Yahr [27] scores
were analysed by means of chi-square tests. All analyses with
regard to group differences in age, disease duration, follow-up pe-
riod and UPDRS motor scores [21], as well as all analyses with
regard to the dependent variables, i.e. the [123I]β-CIT SPECT
binding ratios and asymmetry indices, were analysed by univariate
analysis of variance. Estimates of effect size are reported using eta
squared (η2), which represents the proportion of the total variability
in the dependent variable (i.e. SPECT parameter) that is accounted
for by the independent variable (IPD or APS group membership).
Two of the dependent variables met with the assumption of nor-
mality, which is required for univariate analysis of variance, only
after transformation by means of a natural logarithm (i.e. ipsilateral
and contralateral caudate binding ratio). Correlation analysis be-
tween clinical parameters and [123I]β-CIT SPECT ratios was
performed by means of Pearson bivariate correlation. All analyses
were performed at a significance level of 0.05 (two-tailed). Analysis
was done using the SPSS 11.0 software package (SPSS Inc.,
Chicago, USA).
Results
Analysis of confounding factors
Patients with IPD and APS did not differ with regard to
age, sex distribution, follow-up period, distribution of side
of onset, disease duration, distribution of modified Hoehn
and Yahr [27] scores or UPDRS motor scores [21].
Analysis of [123I]β-CIT binding in IPD and APS
Group averages of specific to non-specific [123I]β-CIT
SPECT binding ratios, putamen to caudate ratios and
asymmetry indices are listed in Table 2. No significant
differences were found with respect to the [123I]β-CIT
binding ratios in the putamen. Ligand binding was, how-
ever, lower in both ipsilateral (F[1, 71]=9.97; p=0.002;
η2=0.125, Fig. 2) and contralateral (F[1, 71]=5.62; p=
0.020; η2=0.074, not illustrated) caudate nucleus of the
Fig. 1. [123I]β-CIT SPECT image of a healthy volunteer. A standard
anatomical ROI template (constructed according to a stereotactic
atlas and including regions for caudate nucleus, putamen and
occipital cortex) has been placed bilaterally. Transverse slice from
the brain at the level of the striatum (approximately 3 cm above the
orbitomeatal line). Levels of SPECT activity are coded from low
(black) to high (white) and have been scaled to the maximum pixel
value in the image
Table 1. Subject characteristics at baseline
Characteristics IPDa (n=62) APSa (n=10)
Sex (male/female) 39/23 5/5
Age (years, mean ± SD) 60.0±13.3 55.9±9.1
Disease duration (years, mean ± SD) 2.7±2.0 1.7±0.9
Follow-up period (months, mean ± SD) 62±11 61±10
Side of onset (right/left) 33/29 7/3
Modified HY score (1/1.5/2/2.5) 20/3/18/21 2/0/2/6
UPDRS motor score (mean ± SD) 18.4±7.0 22.1±6.0
IPD idiopathic Parkinson’s disease, APS atypical parkinsonian
syndromes, HY Hoehn and Yahr, UPDRS Unified Parkinson’s
Disease Rating Scale
aClinical diagnosis at follow-up. All other data were measured at
baseline
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group of patients with APS relative to the group of pa-
tients with IPD. Furthermore, the putamen to caudate ratio
in the contralateral striatum was higher in the group of
patients with APS relative to the group of patients with
IPD (F[1, 71]=7.20; p=0.009; η2=0.093, Fig. 3). There
was a trend towards a higher putamen to caudate ratio in
the ipsilateral striatum (F[1, 71]=2.97; p=0.089; η2=0.041,
not illustrated). In spite of these differences at group level,
Fig. 2. Scatterplot of specific to
non-specific [123I]β-CIT
SPECT binding ratios in the
caudate nucleus ipsilateral to the
side of onset of first clinical
(motor) symptoms. Solid lines
indicate the mean binding ratios
Table 2. Specific to non-specific [123I]β-CIT SPECT binding ratios, putamen to caudate ratios and asymmetry indices
Putamen binding Caudate binding P/C AI
Contra Ipsi Contra* Ipsi* Contra* Ipsi** Putamen Caudate
IPD (n=62) 1.7±0.5 2.3±0.7 3.6±1.1 4.2±1.2 0.48±0.09 0.56±0.11 0.17±0.91 0.09±0.05
APS (n=10) 1.6±0.8 2.0±1.0 2.9±1.1 3.3±1.4 0.57±0.15 0.62±0.14 0.15±0.12 0.06±0.04
Data are shown as mean ± SD
P/C putamen to caudate ratio, AI asymmetry indices, Contra contralateral to side of onset of first clinical (motor) symptoms, Ipsi ipsilateral
to side of onset of first clinical (motor) symptoms, IPD idiopathic Parkinson’s disease, APS atypical parkinsonian syndromes
*Significantly different between IPD and APS (p0.05)
**Trend towards difference between IPD and APS (p0.1)
Fig. 3. Scatterplot of putamen to
caudate ratios contralateral to
side of onset of first clinical
(motor) symptoms. Solid lines
indicate the mean ratios
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individual patients with APS and IPD could have quite
similar patterns of striatal involvement (Fig. 4). No dif-
ferences were found in asymmetry indices.
Correlation of striatal [123I]β-CIT binding with clinical
parameters in IPD and APS
In patients with IPD, correlation analysis revealed a
significant negative correlation between disease duration
and both contralateral (r=−0.30, p=0.020) and ipsilateral
(r=−0.36, p=0.004) striatal [123I]β-CIT binding. In the
IPD group, significant correlations were also found be-
tween [123I]β-CIT binding and disease stage and severity.
Contralateral striatal [123I]β-CIT binding was negatively
correlated with UPDRS motor score (r=−0.34, p=0.006)
and there was a trend towards a negative correlation with
Hoehn and Yahr stage (r=−0.24, p=0.061). Ipsilateral
striatal [123I]β-CIT binding was negatively correlated with
both UPDRS motor score (r=−0.48, p=0.000) and Hoehn
and Yahr stage (r=−0.40, p=0.001). In patients suffering
from APS, no correlations could be found between striatal
[123I]β-CIT binding and either disease duration or stage or
severity.
Discussion
The results of this study demonstrate that within a cohort
of individuals with an initial clinical diagnosis of IPD,
supported by a loss of striatal [123I]β-CIT binding as ev-
idenced by baseline SPECT imaging, the degree of cau-
date involvement differed between a group of patients later
(re)diagnosed with APS and a group of patients in whom
the diagnosis of IPD was maintained. Caudate [123I]β-CIT
binding was reduced more in those patients later to develop
APS than in patients with IPD. This was reflected both in
caudate [123I]β-CIT binding ratios and in putamen to cau-
date ratios.
A higher degree of caudate involvement in APS relative
to IPD was previously reported by Varrone et al. for MSA
in a study using [123I]β-CIT SPECT [11], and by Antonini
et al. [12] and Messa et al. [13] for PSP using [123I]FP-CIT
and [123I]β-CIT SPECT, respectively. By contrast, others
were unable to find any differences in caudate involvement
between IPD and either PSP or MSA [14–16]. This dis-
crepancy may be related to the fact that in the latter studies
IPD patients were included at more advanced stages of
disease, when caudate sparing in IPD is likely to be less
pronounced. In the present study, we did not observe dif-
ferences in putaminal involvement between APS and IPD.
This is in line with most previous studies [12–16], an
exception being the aforementioned study by Varrone et al.
[11], in which the putamen ipsilateral to the most affected
body half was more severely affected in MSA.
The relative sparing of the caudate nucleus in IPD ob-
served in the present and some previous imaging studies is
in line with the results of post-mortem studies that have
revealed a more severe degeneration of dopaminergic fi-
bres projecting from the ventrolateral tier of the substantia
nigra to the putamen and a relative sparing of projections
to the caudate nucleus in IPD [28, 29]. By contrast, in PSP,
post-mortem studies have shown a diffuse loss of nigros-
triatal projections, resulting in a uniform dopamine deple-
tion throughout the striatum [30, 31]. In MSA, patterns of
degeneration are heterogeneous, with diffuse involvement
of the substantia nigra in some and a pattern analogous to
IPD in others [32].
Varrone et al. reported a less marked asymmetry in the
loss of DAT binding from the putamen in MSA relative to
IPD [11], a result that could not be replicated in the cur-
rent or any of the other previous studies. As far as the
present study is concerned, the absence of a difference
in asymmetry indices between the IPD and APS groups
Fig. 4. Baseline [123I]β-CIT SPECT images of two patients with a
parkinsonian syndrome. Transverse slices from the brain at the level
of the striatum (approximately 3 cm above the orbitomeatal line).
Levels of SPECT activity are coded from low (black) to high (white)
and have been scaled to the maximum pixel value in each individual
image. a Patient suffering from MSA, with relatively spared caudate
binding and significantly reduced putamen binding. b IPD patient
with relatively spared caudate binding and significantly reduced
putamen binding. Note the similarity in the patterns of striatal
involvement in images a and b, a phenomenon which is also
reflected in the overlapping distributions in both Fig. 2 and Fig. 3
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could possibly be related to the fact that all patients en-
rolled in the present study had an initial diagnosis of IPD,
thus leading to a potential overrepresentation of APS pa-
tients with an asymmetrical presentation.
In line with previous studies [5, 8–10, 33], we found
strong correlations between clinical parameters and striatal
[123I]β-CIT binding in IPD patients. No correlations be-
tween clinical parameters and [123I]β-CIT binding were
found in APS patients. An obvious explanation is the rel-
atively small APS group size (n=10), a notion supported
by several fairly high Pearson correlation coefficients (up
to −0.46). Moreover, motor performance in APS patients
is at least partly caused by degeneration of post-synaptic
striatal neurons and may also be influenced by non-do-
paminergic (e.g. cerebellar) mechanisms.
In the present study, the initial diagnosis of IPD was
changed in 13% of cases after a mean clinical follow-up
period of 62 months. In a recent study by Hughes et al.
[4], more than one-quarter of patients with an initial clin-
ical diagnosis of IPD later appeared to be suffering from
an APS. The most likely explanation for the higher initial
diagnostic accuracy in the present study is the use of
baseline DAT SPECT imaging to support the clinical di-
agnosis, thus at least excluding several other causes of
parkinsonism. Another important difference between the
study by Hughes et al. and ours is that in the former study
pathological confirmation of the clinical diagnosis was
available. In spite of a mean disease duration at clinical
follow-up of as much as 92 months in the present study,
we therefore cannot exclude the possibility that some sub-
jects in our study in whom a clinical diagnosis of IPD was
so far maintained may yet turn out to be suffering from an
APS.
Considering the extensive overlap among the values of
individual [123I]β-CIT binding ratios of patients with IPD
and of patients with APS and the similarities of individual
SPECT images of IPD and APS patients, the value of
early-stage DAT SPECT imaging for a later re-diagnosis
of APS in individual cases would appear to be limited.
Quite possibly, however, differentiation between the var-
ious parkinsonian syndromes at the individual level may
be improved by further methodological refinements and/or
use of a combination of imaging techniques. For example,
there is some preliminary evidence from a recent DAT
binding study using positron emission tomography with
[11C]-WIN 35,428 as a ligand that a technique with higher
spatial resolution serves better to distinguish IPD patients
from patients with APS [34]. Alternatively, DAT SPECT
could be combined with SPECT imaging of post-synaptic
striatal elements, such as dopamine D2 receptor imaging
using [123I]IBZM or [123I]iodobenzofuran as ligands [16],
although intact binding to the dopamine D2 receptor does
not seem to exclude incipient MSA or PSP [35].
In conclusion, early-stage [123I]β-CIT SPECT scanning
in untreated patients with an initial clinical diagnosis of
IPD demonstrated a relative sparing of the caudate nucleus
in the group of individuals in whom a diagnosis of IPD was
maintained over an extended follow-up period relative to
the group of individuals later re-diagnosed with an APS. In
spite of this difference at a group level, the predictive value
of early-stage [123I]β-CIT SPECT imaging for a later re-
diagnosis of APS in individual cases remains limited. Fur-
ther methodological and/or technical improvements may
yet provide us with a biological marker that also proves
useful at the level of the individual patient.
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